Risk adjusted net present value: What is the current valuation of Corcept Therapeutics’s Miricorilant?
The revenue for Miricorilant is expected to reach an annual total of $92 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that …